Payment overview · 2025
General Payments
$403.51
27 reported records · 8 companies
Healthcare provider profile · identity verified
Robert W Dickson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SHILOH, NJ · NPI 1851314017
Verified facts
What the public records show
CMS Open Payments records show Robert W Dickson, MD received $403.51 in general payments during 2025 across 27 reported records.
Amgen Inc. accounted for 48.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Paxlovid, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $196.93 | 48.8% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63.64 | 15.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.26 | 12.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.36 | 7.5% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $17.82 | 4.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.59 | 4.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.45 | 3.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.46 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $403.51 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $196.93 | 14 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $196.93 | 14 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.26 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.26 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.89 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.36 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 66 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
66 | 65 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 510 | 136 |
| Simvastatin | Simvastatin | 499 | 143 |
| Losartan Potassium | Losartan Potassium | 455 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 430 | 109 |
| Alprazolam | Alprazolam | 409 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 361 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 356 | 99 |
| Azithromycin | Azithromycin | 340 | 236 |
| Furosemide | Furosemide | 316 | 88 |
| Lisinopril | Lisinopril | 315 | 80 |
| Potassium Chloride | Potassium Chloride | 239 | 72 |
| Zolpidem Tartrate | Zolpidem Tartrate | 225 | 35 |
| Metformin Hcl | Metformin Hcl | 217 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 58 |
| Gabapentin | Gabapentin | 207 | 68 |
| Glipizide Er | Glipizide | 202 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 51 |
| Omeprazole | Omeprazole | 189 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 183 | 47 |
| Montelukast Sodium | Montelukast Sodium | 180 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 172 | 47 |
| Meloxicam | Meloxicam | 162 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 51 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 133 | 83 |
| Levofloxacin | Levofloxacin | 127 | 71 |
| Allopurinol | Allopurinol | 121 | 32 |
| Ezetimibe | Ezetimibe | 120 | 35 |
| Famotidine | Famotidine | 120 | 28 |
| Carvedilol | Carvedilol | 116 | 34 |
| Metformin Hcl Er | Metformin Hcl | 104 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 28 |
| Trazodone Hcl | Trazodone Hcl | 103 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 96 | 25 |
| Methylprednisolone | Methylprednisolone | 93 | 64 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 21 |
| Celecoxib | Celecoxib | 87 | 33 |
| Atenolol | Atenolol | 86 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 38 |
| Ozempic | Semaglutide | 86 | 21 |
| Lorazepam | Lorazepam | 81 | 14 |
| Finasteride | Finasteride | 80 | 23 |
| Glipizide | Glipizide | 80 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 80 | 46 |
| Jardiance | Empagliflozin | 77 | 21 |
| Eliquis | Apixaban | 76 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 74 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 71 | 19 |
| Ramipril | Ramipril | 70 | 15 |
| Spironolactone | Spironolactone | 70 | 16 |
| Clonazepam | Clonazepam | 69 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 69 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 66 | 65 |
| Warfarin Sodium | Warfarin Sodium | 63 | 19 |
| Mupirocin | Mupirocin | 60 | 38 |
| Azelastine Hcl | Azelastine Hcl | 59 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 13 |
| Levetiracetam | Levetiracetam | 58 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 21 |
| Meclizine Hcl | Meclizine Hcl | 54 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 53 | 36 |
| Chlorthalidone | Chlorthalidone | 52 | 12 |
| Farxiga | Dapagliflozin Propanediol | 52 | 13 |
| Donepezil Hcl | Donepezil Hcl | 49 | 15 |
| Naproxen | Naproxen | 49 | 24 |
| Prednisone | Prednisone | 49 | 22 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 49 | 12 |
| Colesevelam Hcl | Colesevelam Hcl | 48 | 13 |
| Cephalexin | Cephalexin | 46 | 30 |
| Metolazone | Metolazone | 46 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Cefuroxime | Cefuroxime Axetil | 43 | 20 |
| Synthroid | Levothyroxine Sodium | 43 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Diazepam | Diazepam | 42 | 12 |
| Nifedipine Er | Nifedipine | 42 | 13 |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Fluconazole | Fluconazole | 41 | 20 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 11 |
| Temazepam | Temazepam | 39 | suppressed |
| Glimepiride | Glimepiride | 38 | 11 |
| Methotrexate | Methotrexate Sodium | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 12 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Digoxin | Digoxin | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 34 | suppressed |
| Telmisartan | Telmisartan | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Cefdinir | Cefdinir | 33 | 30 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Indomethacin | Indomethacin | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 28 |
| Estradiol | Estradiol | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 11 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Metronidazole | Metronidazole | 30 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 23 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Desoximetasone | Desoximetasone | 29 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 13 |
| Bumetanide | Bumetanide | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Zafirlukast | Zafirlukast | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Epinephrine | Epinephrine | 21 | 19 |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 21 | 16 |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 19 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 18 | 14 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 16 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Desloratadine | Desloratadine | 14 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Viberzi | Eluxadoline | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $403.51 · 27 records | Amgen Inc. | AIRSUPRA, AREXVY, MOUNJARO, NEFFY, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error